A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Table 4 Clinical trials based on the use of CRISPR-Cas9 technology to provide more effective and universal CAR-T cell registered in ClinicalTrials.gov (June 2021)

Condition	CAR	Target locus (knocked out)	Phase	Location	Participant number	NCT number
ALL	CD19	MAP4K1 (HPK1)	1	China	40	NCT04037566
NHL	CD19	NA	1	USA	50	NCT04637763
Solid tumor	Mesothelin	PD-1 TRAC	1	China	10	NCT03545815
BCL	CD19 CD20 CD22	N.A	1/2	China	80	NCT03398967
Solid tumor	Mesothelin	PD-1	1	China	10	NCT03747965
BCL	CD19	TRAC B2M	1/2	China	80	NCT03166878

Note: ALL acute lymphoblastic leukemia, BCL B cell lymphoma, TRAC T cell receptor alpha constant, B2M beta-2-microglobulin, PDCD1 or PD1 programmed cell death protein 1, NHL non-Hodgkin lymphoma, MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1, NA not available

ISSN: 1757-6512